{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-008621","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.667197+00:00","generated_at":"2026-05-15T15:31:55.912077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Opus Genetics reports FY2025 net loss $49.6M; cash $70.1M; PDUFA date Oct 2026","bullets":["Net loss $49.6M ($0.80/sh) vs $57.5M ($2.15/sh) in 2024; revenue $14.2M from Viatris collab.","Cash $45.1M at Dec 31, 2025; raised $25M in private placement to $70.1M; runway into H1 2028.","BEST1 gene therapy: sentinel patient showed 12-letter BCVA gain and 23% CST decrease; three-month data from full cohort expected mid-2026.","FDA set PDUFA date Oct 17, 2026 for Phentolamine Ophthalmic Solution 0.75% for presbyopia.","Phase 3 LCA5 trial enrolling; RDEP review submission planned Q1 2026; MERTK funding secured from Abu Dhabi fund."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-008621","json":"https://secwatch.observer/filing/0001140361-26-008621.json","markdown":"https://secwatch.observer/filing/0001140361-26-008621.md","text":"https://secwatch.observer/filing/0001140361-26-008621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/0001140361-26-008621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/ef20067388_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:31:55.912077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88de07195dd2d65e58094d1c71c827b6db4a6092","claim":"Opus Genetics, Inc. reported the year ended December 31, 2025 results: revenue $14.2 million.","evidence_excerpt":"Revenue : License and collaborations revenue totaled $14.2 million for the year ended December 31, 2025, compared to $11.0 million for the same period in 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/0001140361-26-008621-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$14.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}